Journal article
Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy
LR Lopes, S Garcia-Hernández, M Lorenzini, M Futema, O Chumakova, D Zateyshchikov, M Isidoro-Garcia, E Villacorta, L Escobar-Lopez, P Garcia-Pavia, R Bilbao, D Dobarro, M Sandin-Fuentes, C Catalli, B Gener Querol, A Mezcua, J Garcia Pinilla, T Bloch Rasmussen, A Ferreira-Aguar, P Revilla-Martí Show all
European Heart Journal | OXFORD UNIV PRESS | Published : 2021
Abstract
Aims: The aim of this study was to determine the frequency of heterozygous truncating ALPK3 variants (ALPK3tv) in patients with hypertrophic cardiomyopathy (HCM) and confirm their pathogenicity using burden testing in independent cohorts and family co-segregation studies. Methods and results: In a discovery cohort of 770 index patients with HCM, 12 (1.56%) were heterozygous for ALPK3tv [odds ratio(OR) 16.11, 95% confidence interval (CI) 7.94-30.02, P = 8.05e-11] compared to the Genome Aggregation Database (gnomAD) population. In a validation cohort of 2047 HCM probands, 32 (1.56%) carried heterozygous ALPK3tv (OR 16.17, 95% CI 10.31-24.87, P < 2.2e-16, compared to gnomAD). Combined logarithm..
View full abstractGrants
Awarded by UK Research and Innovation
Funding Acknowledgements
Luis R Lopes is funded by a Medical Research Council (MRC) Clinical Academic Research Partnership (CARP) award (MR/T005181/1). The work at UCL was funded by the British Heart Foundation Program Grant (RG/15/8/31480) and the National Institute for Health Research University College London Hospitals Biomedical Research Centre. Other funding includes grant and fellowship support from National Health and Medical Research Council of Australia (E.R.P., D.A.E.), Australian Research Council (E.R.P.), Heart Foundation of Australia (E.R.P.), The Stafford Fox Medical Research Foundation (E.R.P., D.A.E.), and the Royal Children's Hospital Foundation (D.A.-B., E.R.P., D.A.E.).